The phrase "a composition of matter" is correct and usable in written English.
It is typically used in scientific or legal contexts to refer to a specific type of substance or material that is made up of various components.
Example: "The patent application describes a composition of matter that includes a novel blend of polymers and additives."
Alternatives: "a material formulation" or "a substance mixture".
On the one hand, the legal process continues to separate DNA as a "composition of matter" from DNA as information which is not patentable.
The implication is not that there will be no patents or the various controversies will be settled; these are likely to intensify as more legal work will be needed to separate DNA as a composition of matter from DNA as an informatic entity.
A.A.P., S.G., A.V.S.H. and H.M.S. are named inventors on a composition of matter patent for MVA85A, and are shareholders in a Joint Venture formed for the further development of this vaccine.
To directly infringe a claim that is directed to a composition of matter (such as DNA) that comprises elements 1, 2 and 3, one needs to make a composition that includes at least elements 1, 2 and 3.
H. Mc is named inventor on a composition of matter patent for MVA85A owned by the University of Oxford, and shareholder in a Joint Venture formed for the further development of this vaccine.
However, the two other judges dismissed this view because the crystal compound was a synthetic, man-made compound, and thus is a "composition of matter" that is eligible for patent protection.
Its implication is that the legal focus on DNA as a compositions of matter is situated in the context of the convergence of the life sciences and informatics alongside the introduction of open source models.
Pfizer's Lipitor, a cholesterol medicine, and Plavix, a blood thinner produced by Bristol-Myers Squibb and Sanofi-Aventis, will have their patents challenged later this year or early next.In general, composition-of-matter lawsuits are considered harder to win than other avenues of attack employed by generic drugmakers to hack away at the thicket of patents that guard blockbuster medicines.
Unfortunately, by the time a new drug is approved for its first indication, there is typically less than 10 years on the original 20 year composition-of-matter patent remaining, 7 which is not enough time to generate the data needed to approve the drug for a second indication and make a profit.
In keeping with such a composition of the white matter is the fact that nociceptive responses have been recorded in the dorsal column nuclei (Ferrington et al. 1988; Cliffer et al. 1992; Usunoff et al. 2006; Zhao et al. 2011).
If your novel idea is a process/method or composition of matter, you can apply for patent protection.
